RPA2 and cancer: Within the pan-cancer cohort, we identified 80 cases with 55 germline heterozygous RPA1, RPA2 or RPA3 variants meeting criteria of AF < 0.5% in gnomAD non-cancer cohort and CADD score > 15 for candidate variant selection (Figure 1A).